Relay Therapeutics, Inc.

RLAY · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.6%

Institutions113.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$15.36M	$10.01M	$1.38M	$3.03M	$82.65M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$302.74M	-$372.47M	-$299.27M	-$364.70M	-$55.80M
Operating income as a percentage of revenue.	-1971.6%	-3722.1%	-21670.9%	-12040.2%	-67.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$276.48M	-$337.71M	-$290.51M	-$363.87M	-$52.41M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.61	$-2.36	$-2.59	$-3.82	$-5.40
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.61	$-2.36	$-2.59	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$84.02M	$124.29M	$151.79M	$280.12M	$447.65M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$621.33M	$871.30M	$1.10B	$1.01B	$799.83M
Everything the company owes — debt, unpaid bills, and other obligations.	$54.27M	$93.50M	$149.55M	$110.64M	$36.54M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$567.06M	$777.79M	$950.22M	$897.81M	$763.29M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$235.46M	-$249.11M	-$229.49M	-$74.41M	-$102.49M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$410000	$2.02M	$9.06M	$3.47M	$1.93M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$235.87M	-$251.13M	-$238.55M	-$77.88M	-$104.42M

	You	Peer avg
P/E	–	12.6
Revenue Growth	-48.3%	+34.1%
ROE	-36.8%	-371.9%

Relay Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles